Early Prediction of Nonresponders to Treatment with Interferon Alpha-2B and Ribavirin in Patients with Chronic Hepatitis C by Louis WC Liu, George Tomlinson, Tony Mazzulli, Alison Murray, Jenny Heathcote

“…BACKGROUND: Treatment of chronic hepatitis C virus (HCV) infection with interferon alpha-2b and ribavirin is costly in terms of side effects, medical resources and drug costs. …”
Get full text

Elderly Patients Are at Greater Risk of Cytopenia During Antiviral Therapy for Hepatitis C by CG Nudo, P Wong, N Hilzenrat, M Deschênes

“…The results of antiviral therapy for hepatitis C virus (HCV) have improved recently with the use of pegylated interferon (PEG-IFN)/ribavirin (RBV) combination therapy. …”
Get full text

Identification of Acute Vaccine-Preventable Hepatitis in Individuals with Chronic Hepatitis in British Columbia between 1991 and 2007 by Lily Fang, Amanda Yu, Jane A. Buxton

“…PURPOSE: To assess the effectiveness of BC public health follow-up of HBV and hepatitis C virus (HCV) cases and immunization policy by determining the number of vaccine-preventable acute hepatitis infections reported following a chronic HBV or HCV diagnosis, by examining demographic characteristics and by observing temporal trends.…”
Get full text

Antidepressant Prophylaxis Reduces Depression Risk but Does Not Improve Sustained Virological Response in Hepatitis C Patients Receiving Interferon Without Depression at Baseline:... by Awad Al-Omari, Juthaporn Cowan, Lucy Turner, Curtis Cooper

“…BACKGROUND: Depression complicates interferon-based hepatitis C virus (HCV) antiviral therapy in 10% to 40% of cases, and diminishes patient well-being and ability to complete a full course of therapy. …”
Get full text

Outcomes of Peginterferon Alpha-2a and Ribavirin Hepatitis C therapy in Aboriginal Canadians by Curtis L Cooper, Robert J Bailey, Vince G Bain, Frank Anderson, Eric M Yoshida, Mel Krajden, Paul Marotta, for the Canadian Pegasys Study Group

“…BACKGROUND: There is little published information on baseline characteristics and therapeutic outcomes in hepatitis C virus (HCV)-infected Aboriginal Canadians. …”
Get full text

Determinants of Antiviral Treatment Initiation in a Hepatitis C-infected Population Benefiting from Universal Health Care Coverage by Romain Moirand, Marc Bilodeau, Suzanne Brissette, Julie Bruneau

“…BACKGROUND AND AIMS: In view of increasing therapeutic efficacy, the delivery of hepatitis C virus (HCV) antiviral treatment is expected to increase. …”
Get full text

Predictors of Antiviral Therapy in a Post-Transfusion Cohort of Hepatitis C Patients by Maciej Witkos, Qi-Long Yi, Jenny Heathcote, Moira K Kapral, Murray D Krahn

“…INTRODUCTION: In the past, antiviral therapy has been given to 15% to 30% of patients infected with hepatitis C virus (HCV). The efficacy of therapy has recently improved with the addition of ribavirin and pegylated interferon. …”
Get full text

Fasciitis Complicating Subcutaneous Injection of Interferon Beta by Curtis L Cooper, Rachel Gerstein, Kelly Kaita

“…Data pertaining to 65 patients treated at the Health Sciences Center Hepatology Research Unit in Winnipeg, Manitoba describing local complications related to subcutaneous interferon (IFN) injection administered to treat hepatitis C virus infection are presented. Nine patients experienced local erythematous reactions at the injection region. …”
Get full text

Association between Leptin, Metabolic Factors and Liver Histology in Patients with Chronic Hepatitis C by Robert P Myers, Djamila Messous, Thierry Poynard, Francoise Imbert-Bismut

“…BACKGROUND: Steatosis is common in hepatitis C virus (HCV)-infected patients and likely accelerates fibrosis progression. …”
Get full text

TLRs, Alcohol, HCV, and Tumorigenesis by Keigo Machida

“…Ample epidemiological evidence suggests that there is a strong synergism between hepatitis C virus (HCV) and alcoholic liver diseases (ALD). …”
Get full text

Hepatitis B and Hepatitis C Viral Infections in Patients with Chronic Lymphocytic Leukemia by Gerald Y Minuk, Betty Lerner, Spencer B Gibson, James B Johnston, Julia Uhanova, Anton Andonov, Jun Wu

“…BACKGROUND: Whether chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections contribute to the pathogenesis and/or course of chronic lymphocytic leukemia is unclear.…”
Get full text

Viral Response to Specifically Targeted Antiviral Therapy for Hepatitis C and the Implications for Treatment Success by Curtis L Cooper

“…Currently, hepatitis C virus (HCV) antiviral therapy is characterized by long duration, a multitude of side effects, difficult administration and suboptimal success; clearly, alternatives are needed. …”
Get full text

CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian Guidelines for the Treatment of Hepatitis C Infection in HIV-hepatitis C Coinfected Adu... by Mark Hull, Stephen Shafran, Alice Tseng, Pierre Giguère, Marina B Klein, Curtis Cooper

“…BACKGROUND: Hepatitis C virus (HCV) coinfection occurs in 20% to 30% of Canadians living with HIV and is responsible for a heavy burden of morbidity and mortality. …”
Get full text

SEROPREVALENCE OF HEPATITIS C AMONG THE APPARENTLY HEALTHYBLOOD DONORS OF KARACHI by Maeesa Wadood et al

“…Pakistan is among the prevalent countries for hepatitis C virus (HCV). Due to poverty, unemployment, low literacy rate, unawareness and poor health facilities, Pakistani population are susceptible to HCV transmission. …”
Get full text

The Many Difficulties and Subtleties in the Cognitive Assessment of Chronic Hepatitis C Infection by Jefferson Abrantes, Daniel Simplicio Torres, Carlos Eduardo Brandão – Mello

“…Often, patients with hepatitis C virus (HCV) complain of cognitive impairment even before the development of hepatic cirrhosis, which they described as “brain fog.” …”
Get full text

Outcomes of Chronic Hepatitis C Therapy in Patients Treated in Community Versus Academic Centres in Canada: Final Results of APPROACH (A Prospective Study of Peginterferon alfa-2a... by Robert P Myers, Curtis Cooper, Morris Sherman, Richard Lalonde, Helga Witt-Sullivan, Magdy Elkashab, Paul Harris, Rob Balshaw, Christopher Usaty, Paul J Marotta

“…BACKGROUND: In patients chronically infected with the hepatitis C virus (HCV), it is not established whether viral outcomes or health-related quality of life (HRQoL) differ between individuals treated at academic or community centres.…”
Get full text

Antineutrophil Cytoplasmic Antibody Induction due to Infection: A Patient with Infective Endocarditis and Chronic Hepatitis C by Fareed B. Kamar, T. Lee-Ann Hawkins

“…We describe an encounter with a 43-year-old male with chronically untreated hepatitis C virus infection who featured ANCA positivity while hospitalized with acute bacterial endocarditis. …”
Get full text

Failure of Ketoprofen and Interferon Combination Therapy to Improve Interferon-Resistant Chronic Hepatitis C by Frank H Anderson, Lecheng Zeng, Eric M Yoshida, Natalie R Rock

“…Serum aminotransferases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) and serum hepatitis C virus (HCV) RNA were analyzed before and throughout treatment. …”
Get full text

Single-Dose Infliximab in Hepatitis C Genotype 1 Treatmentnaive Patients with High Serum Levels of Tumour Necrosis Factor-Alpha Does Not Influence the Efficacy of Pegylated Interfe... by Curtis Cooper, Stephen Shafran, Susan Greenbloom, Robert Enns, John Farley, Nir Hilzenrat, Kurt Williams, Magdy Elkashab, Nabil Abadir, Manuela Neuman

“…BACKGROUND: Serum tumour necrosis factor-alpha (TNF-α) levels correlate negatively with hepatitis C virus (HCV) antiviral response.…”
Get full text

Pilot Study of Ofloxacin and Interferon-Alpha Combination Therapy for Chronic Hepatitis C without Sustained Response to Initial Interferon Therapy by Masafumi Komatsu, Tohru Ishii, Tsuyoshi Ono, Takao Hoshino, Tomoyuki Kuramitsu, Takashi Goto, Tomoo Fujii, Itaru Toyoshima, Mitsuro Chiba, Osamu Masamune

“…For the IFN plus OFLX group, OFLX was administered for 12 weeks at a daily dose of 600 mg. Levels of hepatitis C virus RNA declined significantly from the first month after the start of IFN treatment compared with those before administration in both groups. …”
Get full text